Home › Funds › Avoro Capital Advisors LLC › SYRE
Avoro Capital Advisors LLC position in SYRE
SPYRE THERAPEUTICS INC · Health Care
Avoro Capital Advisors LLC reported holding 2,598,973 shares of SYRE (SPYRE THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$47.8M, representing 0.49% of its reported portfolio and ranking #23 among its reported holdings. Avoro Capital Advisors LLC has disclosed SYRE holdings in 6 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How Avoro Capital Advisors LLC's SYRE position evolved
Avoro Capital Advisors LLC first disclosed a stake in SYRE in Q3 2023 at 11,458 shares (US$140K). The position peaked in Q1 2024 at 1,839,138 shares, worth US$69.8M. Across 6 filings, Avoro Capital Advisors LLC increased the stake 1 time(s), trimmed it 1 time(s) and left it unchanged 2 time(s). The most recent filing (Q3 2026) shows 2,598,973 shares valued at US$47.8M. Notable position changes include a 15951% increase in Q4 2023 (shares rose 9% over the following quarter), a 67% trim in Q3 2024.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 11.46K | $140.36K | New |
| Q4 2023 | 1.84M | $39.58M | Add |
| Q1 2024 | 1.84M | $69.76M | Hold |
| Q2 2024 | 1.84M | $43.24M | Hold |
| Q3 2024 | 598.60K | $17.60M | Reduce |
| Q3 2026 | 2.60M | $47.83M | New |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About SYRE and 13F data
SYRE (SPYRE THERAPEUTICS INC) is a Health Care company. 64 other funds we track also report a position in SYRE — the largest reported positions include Paradigm Biocapital Advisors LP (US$396.8M), PERCEPTIVE ADVISORS LLC (US$383.5M), RTW INVESTMENTS, LP (US$328.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding SYRE
- Paradigm Biocapital Advisors LP 4.46M sh · $396.85M · Q3 2026
- PERCEPTIVE ADVISORS LLC 4.32M sh · $383.48M · Q2 2026
- RTW INVESTMENTS, LP 3.69M sh · $328.68M · Q3 2026
- Venrock Adviser, LLC 2.99M sh · $265.05M · Q2 2026
- DRIEHAUS CAPITAL MANAGEMENT LLC 2.76M sh · $245.76M · Q3 2026
- TCG Crossover Management, LLC 1.90M sh · $169.21M · Q3 2026
- TANG CAPITAL MANAGEMENT LLC 1.89M sh · $167.99M · Q2 2026
- Affinity Asset Advisors, LLC 1.28M sh · $113.88M · Q3 2026
- Remedium Capital Partners, LLC 1.16M sh · $103.33M · Q3 2026
- BRAIDWELL LP 879.47K sh · $78.08M · Q2 2026
- Siren, L.L.C. 868.60K sh · $77.33M · Q3 2026
- Commodore Capital LP 846.79K sh · $75.18M · Q2 2026
More on Avoro Capital Advisors LLC
FAQ
How long has Avoro Capital Advisors LLC held SYRE?
Avoro Capital Advisors LLC has disclosed SYRE holdings in 6 of the last 13 reported quarters, going back to Q3 2023.
What is Avoro Capital Advisors LLC's current position in SYRE?
As of Q3 2026, Avoro Capital Advisors LLC holds 2.60M shares of SYRE (SPYRE THERAPEUTICS INC), valued at $47.83M, representing 0.49% of its reported portfolio and ranking #23.
Has Avoro Capital Advisors LLC been buying or selling SYRE?
In the latest 13F filing (Q3 2026), Avoro Capital Advisors LLC newly opened its position in SYRE. The position peaked in Q1 2024 at 1.84M shares.
Which other funds hold SYRE?
Other major institutional holders of SYRE include Paradigm Biocapital Advisors LP, PERCEPTIVE ADVISORS LLC, RTW INVESTMENTS, LP, among 64 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.